HER2-positive breast cancer: Incidence, prognosis, and treatment options. Am J Cancer 2003; 2 (3): 169-79.Estevez LG, Seidman AD. HER2-positive breast cancer: incidence, prognosis, and treatment options. Am J Cancer. 2003; 2 :169–179....
Expression of CD44+/CD24 was found to be an independent negative indicator for prognosis and a predictive marker for trastuzumab response in HER2-postive primary breast cancers, although not in metastatic breast cancer. Further investigations on the clinical implications of BCSCs in HER2-positive ...
[9] Darlix A, Louvel G, Fraisse J, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019,121 (12), 991–1000. [10] Hackshaw MD, Danysh HE, Henderson...
Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L (1995) Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 75 (Suppl 6): 1320–1326 Article CAS...
Trastuzumab resistance is one of the causes of poor prognosis in patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC). The truncated isoform of dopamine- and cAMP-regulated phosphoprotein (t-DARPP) has been reported to be involved in trastuzumab thera...
[7]Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial.ESMO 2022.139MO [8]HER2DX genomic test in HER2-positive/hormone receptor-positive(HER2+/HR+)brea...
[21]Li S, Shen Y, Wang M, et al. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis. Oncotarget 2017;8(19):32043-32054. [22]Browne IM, André F, Chandarlapaty S, et al. Optimal targeting of PI3K-AKT and mTOR in advanced oestroge...
16. Loibl S, Untch M, Buyse M, et al. Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC). Cancer Res. 2020;80(4_Suppl):P5-06-02.
asHER2-amplified cfDNA was detected in two HER2-negative patients following primary breast cancer treatment. It has been reported that this indicates a poor prognosis (Wulfing et al, 2006); it is not clear whether these cells represent a switch in phenotype or a subgroup of pre-existing cells...
Young*,1,2 1School of Medicine and Medical Science, Saint Vincent's University Hospital, Dublin, Ireland; 2Conway Institute, University College Dublin, Dublin, Ireland; 3School of Mathematical Sciences, Dublin, Ireland Overexpression of HER2 is associated with an adverse prognosis in breast cancer....